XML 31 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Subsequent Events
6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
On July 28, 2016, Roche provided notice that they would be discontinuing its collaboration with the Company and its development of INO-1800, the Company’s DNA immunotherapy against the hepatitis B virus. The termination will be effective 90 days after the date of notice. All of Roche’s rights to INO-1800, including the right to license the product to other parties, will be returned to the Company.

Between July 1, 2016 and July 28, 2016, the Company sold 64,076 shares of common stock under its Sales Agreement for net proceeds of $605,000.